Human Trials

Eureka initiates trial to evaluate ET140203 ARTEMIS T Cell Therapy in HCC

Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the Company has initiated a Phase I/II clinical trial of its ET140203 ARTEMIS T cell therapy in adult patients with hepatocellular carcinoma (HCC), the predominant type of liver cancer. The Phase I portion of the ARYA-1 study is now open for enrollment.

Alnylam reports positive results from ILLUMINATE-B phase 3 study of Lumasiran

Alnylam Pharmaceuticals announced positive topline results from the ILLUMINATE-B pediatric Phase 3 study of lumasiran, an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – in development for the treatment of primary hyperoxaluria type 1 (PH1).

Kuur Therapeutics announces first patients dosed with allogeneic CAR-NKT cell therapy

Kuur Therapeutics, a leader in the development of off-the-shelf CAR-NKT cell immunotherapies for the treatment of hematological and solid malignancies, today announced the treatment of the first patients in its ANCHOR phase 1 study of KUR-502, an allogeneic CAR-NKT therapy.

MedinCell begins first Covid-19 clinical study with Ivermectin

French clinical-stage pharmaceutical firm MedinCell has commenced the first clinical trial of its Covid-19 prevention programme.

ViiV begins implementation science study for HIV treatment regimen candidate in Europe

ViiV Healthcare announced the start of the CARISEL study (Cabotegravir And Rilpivirine Implementation Study in European Locations), which aims to evaluate the best approaches to implementing an investigational, every-two-month, injectable HIV treatment regimen into clinical practice in Europe.

Inovio announces partial hold on Covid-19 vaccine candidate trial over FDA queries

Inovio has announced the partial hold on its planned phase 2/3 trial of its Covid-19 vaccine candidate INO-4800 due to additional queries from the US Food and Drug Administration (FDA).

Arena doses first subject in ELEVATE UC 12 phase 3 trial of Etrasimod in ulcerative colitis

Arena Pharmaceuticals announced that the first subject has been dosed in the ELEVATE UC 12 global Phase 3 trial evaluating etrasimod, an investigational, next-generation, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator, for the potential treatment of moderately to severely active ulcerative colitis.

Millendo Therapeutics initiates first-in-human clinical trial of MLE-301

Millendo Therapeutics announced dosing of the first subject in a Phase 1 clinical trial evaluating the safety, pharmacokinetics and preliminary efficacy of MLE-301, a selective neurokinin 3 receptor (NK3R) antagonist that is being developed for the treatment of VMS, commonly known as hot flashes and night sweats, in menopausal women.

OncoImmune’s SACCOVID demonstrates significant therapeutic efficacy in Covid-19 trial

OncoImmune announced that its investigational immunomodulator SACCOVID (CD24Fc) has demonstrated significant therapeutic efficacy in the phase III SAC-COVID clinical trial.